Iceland· IS-EU/1/16/1108/001-004

Qtern

A saxagliptin and dapagliflozin product containing saxagliptinum inn hýdróklóríð,dapagliflozinum inn própandíól, registered in Iceland by AstraZeneca AB*. The same ATC class is registered in 11 of our 19 countries.

ATC A10BD21

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedQternATCA10BD21REGISTER NO.IS-EU/1/16/1108/001-0…PACKS LISTED0CHECKEDSeptember 29, 2026

Where it is registered

Saxagliptin and dapagliflozin is registered in 11 of 19 countries.

Countries holding a registration under ATC A10BD21 (saxagliptin and dapagliflozin), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 7 of them publish a price we can compare per daily dose

Saxagliptin and dapagliflozin · ATC A10BD21

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Saxagliptinum INN hýdróklóríð,Dapagliflozinum INN própandíól
Manufacturer
AstraZeneca AB*
Country
Iceland (IS)
ATC code
A10BD21
ATC class
Saxagliptin and dapagliflozin
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Saxagliptin and dapagliflozin in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All saxagliptin and dapagliflozin products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Qtern
  • Norway · Qtern

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/839f2172-e3b0-4a98-abe8-c5263e0832a7
GET /v1/drugs/839f2172-e3b0-4a98-abe8-c5263e0832a7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmuhúðuð tafla",
  "source": "lyfjastofnun",
  "atc_raw": "A10BD21",
  "marketed": false,
  "strength": "5 mg/10 mg",
  "ma_number": "EU/1/16/1108/001-004",
  "substance": "Saxagliptinum INN hýdróklóríð,Dapagliflozinum INN própandíól",
  "other_info": null,
  "legal_status": "(R) Lyfseðilsskylt",
  "ma_issued_serial": "42566"
}

See everything about saxagliptin and dapagliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.